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Detecting aggregated amyloid peptides (Aβ plaques) presents targets for developing biomarkers of Alzheimer’s disease (AD).
Polymeric n-butyl-2-cyanoacrylate (PBCA) nanoparticles (NPs) were encapsulated with radiolabelled amyloid aﬃnity 125I-
clioquinol (CQ, 5-chloro-7-iodo-8-hydroxyquinoline) as in vivo probes. 125I-CQ-PBCA NPs crossed the BBB (2.3±0.9ID/g) (P<
.05)intheWTmouse(N =210),comparedto 125I-CQ(1.0±0.4ID/g). 125I-CQ-PBCANPbrainuptakeincreasedinADtransgenic
mice(APP/PS1)versusWT(N =38;2.54×105±5.31×104 DLU/mm2;versus1.98×105±2.22×104 DLU/mm2)andinAPP/PS1/Tau.
Brain increases were in mice intracranially injected with aggregated Aβ42 peptide (N = 17; 7.19 × 105 ± 1.25 × 105 DLU/mm2),
versus WT (6.07×105 ±7.47×104 DLU/mm2). Storage phosphor imaging and histopathological staining of the plaques, Fe
2+ and
Cu
2+, validated results. 125I-CQ-PBCA NPs have speciﬁcity for Aβ in vitro and in vivo and are promising as in vivo SPECT (123I),
or PET (124I) amyloid imaging agents.
Copyright © 2009 Celeste A. Roney et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Alzheimer’sdisease(AD),aneurodegenerativedisorderprin-
cipally of the elderly, is the most prevalent form of dementia.
The cognitive decline associated with AD drastically aﬀects
the social and behavioral skills of patients living with
this disease. Notwithstanding the social impact, AD, also
places great ﬁnancial burdens on patients, families, and the
community as a whole. Furthermore, therapeutic strategies
to probe the central nervous system (CNS) are limited by
the restrictive tight junctions at the endothelial cells of the
blood brain barrier (BBB). To overcome the impositions of
the BBB, polymeric biocompatible drug carriers have been
applied to the CNS for many applications, including cancers;
however, the ﬁeld of drug carrier technology is not well
developed in AD research [1]. Polymeric nanoparticles are
promising candidates in the investigation of AD since they
are capable of opening tight junctions [2] crossing the BBB
[3], high drug loading capacities, and targeting the mutant
proteins of Alzheimer’s [4, 5].
Markedly elevated concentrations of zinc, copper, and
iron in Aβ deposits of the AD brain are well documented
in the literature [6, 7]. Cherny et al. have employed the
antibiotic and Cu/Zn-selective metal chelator, CQ, to inhibit
Aβ accumulations in AD APP2576 transgenic (Tg) mice.
Oral treatments with CQ reduced Aβ deposition by ≈49%
and produced no neurotoxicity in a blinded study. The
authors [8] speculate that CQ’s action on the peptide
may facilitate H2O2 inhibition [8]. Moreover, the authors
validated the selectivity of CQ since systemic metal depletion
was not found [8]; CQ does not deplete brain tissue of
metals, but rather binds to the Aβ-metal complex itself.
In in vivo experiments with nontransgenic animals
treated with CQ, Yassin et al. conﬁrmed signiﬁcant decreases
in the cerebral concentrations of Cu, Zn, and Fe metal ions
[9]. However, in Cherny’s studies of APP2576 Tg mice,
the inhibition of Aβ deposition by CQ caused signiﬁcant
increases in the cerebral concentrations of Cu and Zn [8].
This is because APP transgene expression reduces Cu and Zn2 International Journal of Alzheimer’s Disease
levels in vivo, while the Aβ concentration steadily rises [10].
There are a few possibilities for the decrease. For example,
the metal ions may be eﬄuxed by Aβ, or APP/Aβ may
prevent reuptake of the ions [11]. Despite the mechanism,
CQ prevents uptake; of the metals by the protein. This action
aﬀords metallic access to peripheral brain tissue, and the
metal ion concentration increases. Since AD is a syndrome
ofmetaldyshomeostasis,CQmaybeabletorestorethemetal
metabolism to its normal state.
Opazo et al. [12] have explored the Aβ-plaque binding
properties of radioiodinated CQ in APP2576 Tg mice
([125I]CQ; higher brain retention compared with controls
on autoradiography), and in AD patients ([123I]CQ; more
rapid uptake compared with age-matched healthy controls).
SPECT imaging was limited due to low tracer uptake,
however, CQ was shown to localize with Aβ pathology [12].
Notably, the authors [12] synthetically precipitated Aβ1–40
and Aβ1–42 by in vitro methods. The synthetic β-amyloid
demonstrated 125ICQ saturation, which was directed by
Zn2+; the 125ICQ binding was displaced by the heavy metals
Zn2+ and Cu2+, the metal chelator DTPA, and the amyloid
aﬃnity dye Congo red. Enhancement of Zn2+-125ICQ was
alsoshowninconcentratedfractionsofAβfrompostmortem
AD brain. These results validate the eﬀectiveness of CQ as a
β-amyloid detection agent, and most importantly, correlate
literature evidence linking Aβ deposition in AD and cerebral
heavy metals [5, 8].
Our preliminary studies with 125ICQ showed that the
agent crossed the BBB, but was retained too brieﬂy for
eﬀective chelation. Therefore, a drug carrier is required to
improve the extravascular retention of 125ICQ. Polymeric
butylcyanoacrylate(PBCA)nanoparticles(NPs)werechosen
as the drug carrier. Here, we report that 125I-CQ-BCA NPs
act as targeted drug carriers with an aﬃnity for amyloid
plaques. 125I-CQ-PBCA NPs are promising candidates for in
vivo brain imaging of the amyloid plaques.
2. Methods
2.1. Radioiodination of Clioquinol. CQ was radiolabelled
with 125I (Perkin Elmer, Waltham, MA) by the Chloramine-
T (CT) method of radioiodination. Puriﬁcation of 125I-CQ
was performed by solvent extraction in dichloromethane
(DCM) and H2O. The organic layer (e.g., DCM) was
evaporated under N2 gas, and the 125I-CQ was dissolved
in dimethylsulfoxide (DMSO, 1mL). The puriﬁcation of
125I-CQ was analyzed by thin layer radiochromatography
(RTLC). The speciﬁc purity was >95%.
2.2. Synthesis of Polymeric Nanoparticles. The NPs were
polymerized as per the modiﬁed procedure of Kreuter et
al. [13]. A polymerization medium was prepared containing
Dextran 70000 and Tween-80 (polysorbate 80) (both at
a concentration of 1% each in 0.1NHCl) (Sigma, USA);
5.05×106 Bq 125I-CQ was added to the solution just prior to
the addition of butylcyanoacrylate (BCA) monomer. A 1%
(w/v) butylcyanoacrylate solution (Sichelwerke, Hannover,
Germany) was added drop wise during constant magnetic
stirring at 400rpm. After 3 hours of polymerization, the NP
suspension was neutralized with 0.1NNaOH to complete
the polymerization. This solution was ﬁltered with a 0.2μm
ﬁlter and puriﬁed by ultracentrifugation (Beckman Coulter,
Fullerton, CA; 45Krpm, 1h). The pellet was washed and
redispersed in water, which contained 1% Tween-80. The
PBCAnanoparticleswerethenovercoatedwith1%Tween-80
by stirring for 30 minutes in phosphate buﬀer solution (1X
PBS), just before in vivo administration. Nanoparticle size
(45nm) was determined by a Zetasizer 3000HS (Malvern,
Worcestershire, UK).
2.3. In Vitro Labeling of Amyloid Plaques. Cortical frontal
AD and control brain tissue were obtained from the tissue
bank, as approved by our Institutional Review Board (800μL
buﬀer solution of 0.1% FBS) in the presence of 125I-CQ
(1.17 × 104 Bq in 100μL PBS). Brain homogenates were
microcentrifuged (13KRPM, 15 minutes) and the percent
binding was calculated. The experimental results provided
evidence of preferential binding by 125I-CQ to the AD brain
tissue, as compared to cortical control brain tissue.
2.4. Aggregation of the Aβ42 Peptide. Amyloid protein (1–
42), Aβ42, (0.5mg) was purchased from Bachem California
(Torrance, CA), and dissolved in 1.15mL PBS (pH 7.4) to a
ﬁnal concentration of 435μg/mL (100μM) by magnetically
stirring the solution in a closed vessel at 1200RPM for 7
days at room temperature [14]. After 7 days, the aggregated
peptide suspension was visibly cloudy. The aggregated Aβ42
was stored in 100μL aliquots at −20◦C until use.
2.5. Intrahippocampal Sterotaxic Injection of Aggregated Aβ42.
All use of animals was in compliance with the regulations
of the Animal Resources Center (ARC) of UT Southwestern
Medical Center, and approved by the Institutional Review
Board (IRB). All mice were anesthetized intraperitoneal
(IP) with 100–150μL of Ketamine HCL (Sigma, St. Louis,
Mo). Wild type BALB/C mice (Charles River Laboratories,
Wilmington, MA;N = 17)wereinjected bydirectstereotaxis
(Model 900 Small Animal Stereotaxic Instrument, David
Kopf Instruments, Tujunga, CA) with the aggregated Aβ42
peptide at a concentration of 1μg/1μL, and at a constant
ﬂow rate of 60 seconds. A lubricant was placed into the eyes
of the mice to prevent over-drying during the experiments.
The mice received unilateral injections of either saline or the
Aβpeptideaggregate.Theinjectionlocationcorrespondedto
the mouse brain hippocampus structure CA1, at coordinates
−1.5, −1.0, and −1.8, relative to Bregma [15, 16]. The
peptide was allowed to grow for 7 days, during and after
which time cognitive tests for behavior (Y-maze) were
performed.
2.6. In Vivo Imaging of the Plaques by Nanoparticle Adminis-
tration. The 125I-CQ-BCA NPs (1–3mg) were administered
to AD mouse transgenic models by lateral tail vein injection.
The Aβ42 mice received 125I-CQ-BCA NPs at 8 days postin-
jection of the peptide.International Journal of Alzheimer’s Disease 3
InvivoStoragePhosphorautoradiography(PerkinElmer
Cyclone Storage Phosphor Imaging System; OptiQuant
Imaging Software) was used to determine the relative
qualitative diﬀerences in the brain uptakes of 125I-CQ by the
AD mouse models and wildtype control mice. Brieﬂy, each
mouse was anesthetized I.P. with 100–150μL of Ketamine
HCl (Sigma Aldrich, USA) throughout the duration (5–90
minutes) of the imaging experiment. Postinjection of the
radiotracer, the mouse was placed on the phosphor screen
with a lead sheet between the ﬁlm and the animal’s body
in such a way that the only exposed body part was the
head. In this way, background radiation from the body was
minimized, and the activity source projected onto the ﬁlm
was from the animal’s head region only. Regions of interest
(ROI) were drawn in the brain space to obtain information
in semiquantitative units (Dynamic Light Units, DLU) per
volume space (DLU/mm2).
At the conclusion of the imaging experiments, the mice
weresacriﬁced by cardiac perfusion through the left ventricle
with 4% paraformaldehyde. The brains were harvested and
stored in formalin, before being embedded in wax, and
sectioned at a 5μm slice thickness. The slices were stained
with Congo red (amyloid plaques), Prussian blue (Fe2+), and
Rubeanic acid (Cu2+).
2.7. AD Transgenic Mice. Mice with a double mutation
(APP/PS1) for Alzheimer’s disease were commercially pur-
chased (N = 5) from The Jackson Laboratories (Bar Harbor,
ME; strain B6C3-Tg(APPswe, PSEN1dE9)85Dbo/J). This
particular mouse model corresponds to a form of early
onset disease and expresses a mutant human presenilin 1
and a chimeric mouse/human amyloid precursor protein
(APPSwe). The expression of both transgenes was directed
by the mouse prion protein promoter. The APPswePS1
strain was developed on a B6C3HF2 background. The
chimeric APP was modiﬁed to encode the Sweedish muta-
tions K595N/M596L in order to elevate the amount ot
Aβ produced from the transgene, by favoring processing
through the beta-secretase pathway. Mice with the double
mutation (APP/PS1) were generously donated (N = 33) by
Dr. David Russell (UT Southwestern). Mice with the triple
mutation (APP/PS1/Tau) were generated (N = 2) by Dr.
Malu Tansey (UT Southwestern), to express the knock-in
human presenilin 1 mutation, mutant Tau, and the Swedish
APP mutation.
3.StatisticalAnalysis
Data were entered into Excel worksheets (Microsoft Corpo-
ration, Redmond, WA), and analyzed using the non-paired,
two-tailedStudent’st-testwithunequalvariance.P<. 05was
regarded as signiﬁcant.
4. Results
4.1. In Vitro Binding of 125I-CQ to Brain Tissue. 125ICQ was
used in in vitro assays of human postmortem frontal cortex
to test the aﬃnity of the radiolabelled chelator for amyloid
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Figure 1: In vitro binding of 125I-CQ to brain homogenates.
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Figure 2: PBCA Nanoparticles.
plaques. Age-matched normal specimens were tested as
control samples; no AD pathology was found in normal
tissue (i.e., plaques and tangles in the brain). Experimental
results (Figure 1) provide evidence of preferential binding by
125I-CQ to the AD brain tissue (1000μg, 18.5% binding),
as compared to cortical control brain tissue (1000μg,
13% binding). Therefore, an amyloid-aﬃnity drug could
be successfully radiolabelled; the radioligand discriminated
between AD brain tissue and control brain tissue.
4.2. In Vivo Biodistribution of 125I-CQ BCA NPs. The BCA
monomer was polymerized with small particulate diameter
(45nm) and with uniform size distribution (Figure 2). In
vivo biodistribution experiments showed that the free 125I-
CQ had a rapid brain uptake, aswellas rapid blood clearance
in normal mice (Table 1). Furthermore, 125I-CQ cleared the
brain quickly; the % ID/g for the brain at 2 minutes was4 International Journal of Alzheimer’s Disease
Table 1: In vivo biodistribution of 125I-CQ by IV administration in wild type mice (n = 105) (table represents organ uptakes in %ID/g ±
SD).
Time (min) Brain Blood Spleen Liver Brain : blood ratio
21 ±0.49 .2 ±2.82 .6 ±0.11 2 .5 ± 0.80 .1 ±0.1
51 ±0.35 .7 ±1.3N /A1 5 .5 ± 5.60 .2 ±0.01
15 0.3 ±0.12 .9 ±0.71 .2 ±0.13 .8 ±0.70 .1 ±0.1
30 0.3 ±0.12 .3 ±0.41 .3 ± 15 .2 ±2.20 .1 ±0.1
60 0.1 ±0.11 .3 ±0.70 .5 ±0.33 .6 ±2.30 .3 ±0.5
120 0.03 ±0.03 0.1 ±0.10 .6 ±0.41 .3 ±0.50 .2 ±0.1
240 0.04 ±0.02 0.6 ±0.20 .4 ±0.30 .9 ±0.20 .1 ±0.1
P = .05
Table 2: In vivo biodistribution of 125I-CQ-BCA-NPs by IV administration in wild type mice (n = 105) (NP polymerized in the presence of
1% Dextran 70000 and 1% Tween-80; the table represents organ uptakes in %ID/g ± SD).
Time (min) Brain Blood Spleen Liver Brain:bloodratio
22 .3 ±0.91 2 ±2.51 .6 ±0.41 5 ±2.10 .2 ±0.1
51 .5 ±0.97 .9 ±1.61 .8 ±0.51 1 .4 ±1.50 .2 ±0.1
15 0.5 ±0.24 .9 ±1.21 .4 ±0.58 .1 ±2.10 .1 ±0.1
30 0.3 ±0.13 .4 ±1.50 .9 ±0.76 .6 ±2.40 .1 ±0.0
60 0.2 ±0.12 .1 ±1.10 .5 ±0.33 .9 ±1.60 .1 ±0.0
120 0.03 ± 0.00 .7 ±0.20 .2 ±0.03 2.3 ±0.40 .1 ±0.0
240 0.02 ± 0.00 .4 ±0.00 .1 ±0.11 .4 ±0.10 .01 ±0.0
P = .05
AD transgenic mouse with
7.56 ×105 CPM 125ICQ BCA NPs
AD transgenic mouse with
8.06 ×105 CPM 125ICQ
Figure 3: AD transgenic mice injected with 125ICQ BCA NPs and
125I C Q( M i c ea g e d7m o ;1 5m i n u t e sp o s ti n j e c t i o n ) .
Figure 4: AD transgenic mice injected with 125ICQ BCA NPs and
125I C Q( M i c ea g e d7m o ;9 0m i n u t e sp o s ti n j e c t i o n ) .
0.99 ± 0.40%, and at 4 hours, it was 0.04 ± 0.02%. Table 2
shows that when the 125I-CQ was encapsulated within the
BCA NPs, the brain uptake was enhanced. At two minutes,
the wild type mice exhibited 2.31 ± 0.89% uptake of the
125I-CQ BCA NPs in the brain (Table 1). Brain and blood
clearances of the 125I-CQ BCA NPs were rapid; the % ID/g
(brain) at 4 hours was 0.02%. Together, Tables 1 and 2 show
Table 3: 7 month AD transgenic with 9 month control with 125ICQ
BCA NPs in DLU/mm2 (mean±SD); (n = 4).
Time (mins) 9mo control 7mo AD transgenic
10 1.64 × 105 ±1.75 × 104 2.26 ×105 ±4.22 ×105
30 1.76 × 105 ±3.49 × 104 1.63 ×105 ±2.44 ×104
60 1.06 × 105 ±1.57 × 104 7.04 ×104 ±1.14 ×104
90 1.98 × 105 ±2.22 × 104 2.54 ×105 ±5.31 ×104
P = .05; 1mg BCA NP; 795,338 CPM 125ICQ.
that 125I-CQ BCA NPs have an increased brain uptake versus
125I-CQ in the wild type control mouse.
Table 3 shows similar results, in Dynamic Light
Units/mm2 (DLU/mm2), the unit described in
autoradiographic imaging. For example, in the wildtype
control mouse, at 10 minutes post injection the brain
uptake of encapsulated 125I-CQ is 1.64 × 105 ± 1.75 × 104
versus 2.26 × 105 ± 4.22 × 105 in the AD transgenic mouse.
Moreover, the brain uptake is signiﬁcantly greater in the AD
mouse at 90 minutes post injection of 125I-CQ BCA NPs
(1.98×105±2.22×104 wildtypeversus2.54×105±5.31×104
AD transgenic)
Triple transgenic mice, for which mutations in the APP
and Tau genes result in amyloid plaques and neuroﬁbrillary
tangles, were tested against wildtype controls for brain
uptake of 125I-CQ BCA NPs. The in vivo uptake was imaged
by autoradiography, and the data are given (DLU/mm2)
in Table 4. Table 4 shows that at both 60 minutes and
90 minutes post injection of 125I-CQ BCA NPs, the AD
transgenic mouse had a signiﬁcantly greater brain uptakeInternational Journal of Alzheimer’s Disease 5
Table 4: 12 months triple transgenic Mice with 125ICQ BCA NPs in
DLU/mm2 (mean ± SD); (n = 2).
Time (min) Control Triple transgenic
54 .94 ×106 ±1.61 ×106 4.60 ×106 ±1.22 ×106
30 1.53 ×105 ±8.26 ×103 1.77 ×105 ±1.33 ×104
60 3.92 ×106 ±1.49 ×106 6.28 ×106 ±1.68 ×106
90 3.94 ×106 ±5.05 ×105 4.85 ×106 ±1.00 ×105
P = .05; 1mg BCA NP; 2.24 x 106 CPM 125ICQ.
12 mo control 15 mo AD transgenic
Figure 5: 125I C QB C AN P s( 1h o u rp o s t i n j e c t i o n ) .
and retention of the imaging agent, as compared with the
wildtype control. For example, at 60 minutes post injection,
the brain uptake in the AD mouse was 6.28×106±1.68×106
versus 3.92 × 106 ±1.49 ×106 in the wildtype control.
4.3. In Vivo Imaging of the Amyloid Plaques in AD Mouse
Models. The PBCA NPs were successfully loaded with the
radiolabelled quinoline derivative 125I-CQ and delivered to
the mice by intravenous administration. Storage Phosphor
imaging qualitatively showed that the NPs transported the
drug across the BBB. Further, the 125I-CQ labeled the
amyloid deposits.
Figure 3 shows in vivo autoradiographs of the brain
uptakes of 125ICQ BCA NPs and 125ICQ in transgenic mice
(7 months old, APP/PS1), at 15 minutes postadministration
of the nanoparticle-encapsulated drug and the free drug.
The AD transgenic mice have a greater brain uptake with
the use of nanoparticles, as compared to the free 125ICQ;
thus, nanoparticulate encapsulation of 125ICQ enhances
BBB crossing of the drug. Furthermore, nanoparticulate
encapsulation of 125ICQ enhances retention of the drug.
Figure 4 shows in vivo autoradiographs of the brain uptakes
of 125ICQBCANPsand 125ICQintransgenicmice(7months
old, APP/PS1), at 90 minutes post administration of the
nanoparticle-encapsulated drug and the free drug. At 90
minutespostinjection,theADtransgenicmicehaveagreater
brain uptake with the nanoparticles, as compared to the
free 125ICQ. Therefore, transgenic mice have longer brain
retention of the nanoparticle delivered drug, as compared
to the free drug. Figure 5 shows in vivo autoradiographs of
the brain uptakes of 125ICQ BCA NPs in a 12-month wild
typecontrolmouse,andina15-monthADtransgenicmouse
(APP/PS1). At one hour post injection, the AD transgenic
mouse has an increased brain uptake of the nanoparticles,
presumably due to the presence of amyloid plaques.
3 × Tg AD Control
54
Figure 6: 125ICQ BCA NPs triple transgenic mouse model (mice
aged 12 mo; 1 hour postinjection).
Figure 7: Hippocampal pathology in 3 ×Tg Bielschowsky Stain
Figure 8: Aggregated amyloid plaques: 15 mo AD transgenic
mouse.6 International Journal of Alzheimer’s Disease
Transgenic brain Control brain
5μm slice at level of hippocampus
Figure 9: 15 mo AD Transgenic: hippocampal staining of Fe
2+.
Transgenic brain Control brain
5μm slice at level of fourth ventricle
Figure 10: Cu
2+ staining of aggregates in 3 ×Tg (APP/PS1/Tau) mouse.
Experiments with 125ICQ BCA NPs were also done in AD
triple transgenic (3 × Tg) mice (APP/PS1/Tau). In Figure 6,
invivoautoradiographsshowthatatonehourpostinjection,
the AD triple Transgenic mouse had the higher brain uptake
of the nanoparticles (as compared to the wild type control
mouse). Additionally, a Bielchowsky stain (Figure 7)v e r i ﬁ e d
the AD pathology in the 3xTg mouse. Finally, histological
staining of brain slices taken from these AD mouse models
veriﬁed the presence of amyloid (Congo red, Figure 8), Fe2+
(Prussian blue, Figures 9 and 11), and Cu2+ (Rubeanic acid,
Figure 10).
5. Discussion
Cyanoacrylate nanoparticles were speciﬁcally designed for
carrying drugs across the blood-brain barrier in mouse
models of Alzheimer’s disease. In vivo biodistribution of
the 125I-CQ-labelled butylcyanoacrylates in wild-type mice
showed that they crossed the BBB with greater eﬃciency
than the 125ICQ control. The BCA NP was selected as the
prototype drug carrier because it polymerized with the most
reproducibility; it crossed the BBB and had a rapid uptake
and clearance from the normal brain. These parameters are
important in order to validate the PBCA NP as a drug carrier
across the BBB; another unique factor is the lipophilicity
of the carrier. Good lipophilicity assists rapid uptake and
clearance from the normal brain [17]. The lipophilicity of
the nanoparticles was enhanced by surfactant coating with
Tween-80.
The prototype PBCA NP was fully characterized for
physicochemical and stabilizer eﬀect. Smaller sized particles
resulted when the monomer was polymerized at a lower pH,
in the presence of the stabilizer Dextran 70000 (as opposed
to the hydrophilic polyethylene glycol, PEG), and deﬁnitely
in the presence of a surfactant (e.g., Tween-80). Loading
of the nanoparticles with amyloid-aﬃnity drugs, such as
derivatives of the Thioﬂavins (S- or T-), or Congo red did
not signiﬁcantly aﬀect the size of the BCA NPs. Therefore,
theBCANPsmaintainedstabilityupondrugloadinginvitro.
Additional amyloid-aﬃnity drugs have been reviewed in the
literature [2, 17, 18].
The amyloid-aﬃnity chelator CQ was successfully
radioiodinatedwith 125I; 125ICQwasusedininvitroassaysof
human postmortem frontal cortex to test the aﬃnity of the
radiolabelled chelator for amyloid plaques. AutoradiographyInternational Journal of Alzheimer’s Disease 7
Transgenic brain Control brain
5μm slice at level of fourth ventricle
Figure 11: Fe
2+ staining in 3 ×Tg mouse.
validated preferential labeling of the AD tissue by the
125ICQ (compared with control brain tissue). Then, the
125ICQ was successfully encapsulated within PBCA NPs.
125ICQ PBCA NPs preferentially labeled frontal human AD
tissue compared with frontal control tissue. PBCA NPs act
as drug carriers of 125ICQ targeted towards amyloid-beta
plaques, presumably due to chelation of transitional metals
in amyloid plaques.
6. Conclusion
In vivo detection of amyloid plaques for the early diagnosis
of AD is desirable. Presently, histological conﬁrmation of
the plaques and of the neuroﬁbrillary tangles is the only
deﬁnitive mode of diagnosis. This is true despite the fact
that patients typically receive clinical diagnoses based on
cognitive tests, medical histories, and so forth. Noninvasive
in vivo detection aﬀords patients the opportunity to receive
themosteﬀectivepatientcareasearlyaspossible.Likewise,it
allows clinicians the prospect of tracking disease progression
when deﬁnitive treatment becomes available. Hence, health-
care professionals are able to design appropriate therapeutic
strategies.
In vivo detection of amyloid-beta proteins improves
speciﬁcity of diagnosis in noninvasive screening techniques,
such as single photon emission computed tomography
(SPECT) imaging. We have designed polybutylcyanoacrylate
nanoparticles with incorporated radioligands and amyloid
aﬃnity agents that are attracted to the Aβ proteins. Thus,
the clinical potential of the 125ICQ-BCA-NPs is improved
speciﬁcity of diagnostic accuracy in AD detection.
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